CRF awards four global grants to advance CHM research toward new clinical trial endpoints and therapeutic approaches—driving progress toward treatments.

Different groups of people—men, women, children, and people of different races or ethnic backgrounds—respond differently to different drugs. Clinical trials are supposed to drive advances in medicine ...

Otto Metzger, MD - Principal Investigator of AFT-38 PATINA and Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute. January 28, 2026 — Alliance Foundation ...

Trials aim to optimize frontline therapies for CLL, multiple myeloma, SLL, and pediatric acute leukemia/MDS, focusing on high-risk, treatment-naïve patients. Investigations include BTK inhibitors, CAR ...

A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...

Both dosage regimens of amlitelimab were associated with statistically significant improvements in skin clearance and disease severity vs placebo in the US estimand. Topline data were announced from ...

Clinical trials are vital for developing safer, more effective metastatic breast cancer treatments, yet participation is low due to access and financial barriers. Trials progress through phases, from ...

Paramount+ will raise U.S. subscription prices and end free trials starting January 2026. Boy, 9, feels unwell after hike—parents face devastating reason days later Joshua delivers reality check to ...

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...

Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...

In the recently reported NEPTUNUS-1 and -2 trials, presented at this year's American College of Rheumatology (ACR) annual meeting, investigators found that the anti-B-cell activating factor receptor ...